Iobenguane I-131 - Jubilant DraxImage

Drug Profile

Iobenguane I-131 - Jubilant DraxImage

Alternative Names: 131I-iobenguane; 131I-metaiodobenzylguanidine; 131I-MIBG; 3-Iodobenzylguanidine; I-131-MIBG; Iobenguane sulfate; m-Iodobenzylguanidine sulfate

Latest Information Update: 11 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Jubilant DraxImage
  • Developer Jubilant DraxImage; New Approaches to Neuroblastoma Therapy Consortium
  • Class Antineoplastics; Guanidines; Iodobenzenes; Radiopharmaceuticals; Small molecules; Sulfates
  • Mechanism of Action Diagnostic imaging enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Neuroblastoma

Most Recent Events

  • 11 Jul 2018 Chemical structure information added
  • 19 Jun 2018 Jubilant DraxImage plans the OPTIMUM phase II trial for Neuroblastoma (Second-line therapy or greater) in USA , (NCT03561259)
  • 09 Jan 2017 Compassionate Use/Expanded access programme by Northwell Health and Cohen Children's Medical Center is temporarily not available for Neuroblastoma (In infants, In children, In adolescents, In adults, Second-line therapy or greater) and Phaeochromocytoma (In infants, In children, In adolescents, In adults, Metastatic disease, Second-line therapy or greater) in USA (NCT03015844)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top